GENNAO BIO
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
GENNAO BIO
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2020-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.gennao.com
Total Employee:
1+
Status:
Active
Total Funding:
41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Nginx
Similar Organizations
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Current Advisors List
Board_member
2021-05-01
Board_member
Board_member
Current Employees Featured
Elias Quijano Co-founder @ Gennao Bio
Co-founder
Stephen Squinto Co-founder and CEO @ Gennao Bio
Co-founder and CEO
Bruce Turner Co-founder @ Gennao Bio
Co-founder
Joseph McIntosh Chief Medical Officer @ Gennao Bio
Chief Medical Officer
Dr. Peter Glazer, MD, PhD Co-founder @ Gennao Bio
Co-founder
1901-01-01
Julie Hambleton Member Board Of Directors @ Gennao Bio
Member Board Of Directors
2021-07-01
Founder
Investors List
CureDuchenne Ventures
CureDuchenne Ventures investment in Series A - Gennao Bio
OrbiMed
OrbiMed investment in Series A - Gennao Bio
Logos Capital
Logos Capital investment in Series A - Gennao Bio
Surveyor Capital
Surveyor Capital investment in Series A - Gennao Bio
Official Site Inspections
http://www.gennao.com
- Host name: 16.124.215.35.bc.googleusercontent.com
- IP address: 35.215.124.16
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Gennao Bio"
Gennao Bio - First-in-Class, Targeted Nucleic Acid …
Apr 9, 2024 Gennao Bio is developing first-in-class, targeted nucleic acid therapeutics utilizing its proprietary, non-viral GMAB platform technology. ... He also spent five years at Hoffman-La Roche in various positions and helped …See details»
Team Archive - Gennao Bio
Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC) ... Mr. Campbell joined Amicus in 2006 and led the global organization responsible for the …See details»
Gennao Bio - Crunchbase Company Profile & Funding
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that …See details»
Gennao Bio Expands Leadership Team with Two Key Appointments
Jan 6, 2022 Gennao Bio is a genetic medicines company developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) …See details»
Gennao Bio - LinkedIn
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform …See details»
Gennao Bio - Contacts, Employees, Board Members, Advisors
Organization. Gennao Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Number of Board …See details»
Gennao Bio - Overview, News & Similar companies | ZoomInfo.com
Jan 6, 2022 Gennao Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 HOPEWELL, N.J.--(BUSINESS WIRE)- …See details»
Gennao Bio - VentureRadar
" Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform …See details»
Gennao Company Profile 2025: Valuation, Funding
Gennao General Information Description. Developer of targeted nucleic acid therapeutics intended to cure muscle diseases. The company uses gene monoclonal antibody (GMAB) platform technology, that utilizes a novel, cell …See details»
Gennao - VentureRadar
Gennao Bio USA n/a Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody …See details»
Gennao Bio Strengthens Board of Directors with Appointments of …
HOPEWELL, N.J., March 17, 2022 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the …See details»
Gennao Bio Company Profile: Overview and Full News Analysis
Gennao Bio, located in New York, is a biotechnology company focused on developing first-in-class, targeted nucleic acid therapeutics using its proprietary GMAB platform technology. The …See details»
Gennao Bio - Drug pipelines, Patents, Clinical trials - Synapse
Explore Gennao Bio with its drug pipeline, therapeutic area, technology platform, 5 news, Disease Domain:Neoplasms, Technology Platform:Antibody oligonucleotide conjugates, Monoclonal …See details»
Gennao | VentureRadar
Gennao Bio USA n/a Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody …See details»
Gennao Bio - Funding, Financials, Valuation & Investors
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Gennao Bio Closes $40 Million Series A Financing to Develop …
May 10, 2021 Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. Investor …See details»
Gennao Bio Appoints Claudine Prowse, Ph.D., as Chief Financial …
Jul 26, 2021 Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) …See details»
前沿专利 | Gennao Bio — 强强联合的抗肿瘤AOC医药新闻-ByDrug …
Aug 14, 2024 相较于仅通过对3E10进行抗体工程性改造，Gennao Bio采用了更广阔的思路，即核酸递送。 与ADC中的毒素payload不同，基于抗体的核酸递送的一个主要担忧就是核酸若由 …See details»
Gennao Bio Announces Upcoming Presentation at the American …
Apr 4, 2024 Gennao Bio is a genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing its proprietary, non-viral gene monoclonal antibody (GMAB) …See details»
How organizations can harness the power of GenAI for good
Jan 7, 2025 We’re also working with a global automotive company in the field of mobility and AI-enabled telecommunications to help prevent traffic accidents. The company is making safety …See details»